^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Gazyva (obinutuzumab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    07/22/2014
    Excerpt:
    Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.
    Secondary therapy:
    chlorambucil
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody indicated:...in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.
    Secondary therapy:
    chlorambucil
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    08/30/2022
    Excerpt:
    The following regimens are included as options for relapsed/refractory disease regardless of patient’s age or comorbidities...HDMP + rituximab or obinutuzumab (category 2B)
    Secondary therapy:
    methylprednisolone acetate
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma: Useful in Certain Circumstances…Obinutuzumab ± chlorambucil...
    Secondary therapy:
    chlorambucil
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Haematologica
    Title:

    Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

    Excerpt:
    ...overall response rates at three months post treatment exceeded 80% for all obinutuzumab-chemotherapy combinations.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.3324/haematol.2017.186387
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Leukemia
    Title:

    Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

    Excerpt:
    ...CLL patients who received obinutuzumab plus fludarabine and cyclophosphamide (G-FC)...Overall response rate was observed in 90.0%, with 46.4% of patients achieving complete response...Frontline G-FC represents a promising treatment option for fit patients with CLL.
    Secondary therapy:
    cyclophosphamide + fludarabine oral
    Trial ID:
    NCT01905943